Stay updated with breaking news from Small Molecules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic
Lonza Group AG / Key word(s): Sustainability/Miscellaneous03-Apr-2024 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting will take place on 8 May 2024 at the Co...
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The
Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) saw a significant decline in short interest in February. As of February 29th, there was short interest totalling 9,100 shares, a decline of 68.1% from the February 14th total of 28,500 shares. Based on an average daily trading volume, of 65,700 shares, the short-interest ratio is currently […]
Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.